english.prescrire.org > Prescrire International > N°79 - October 2005

n°79

October 2005

Issue Contents
Editorial

Free  Politics

p.162

New Products


Aripiprazole (New Drug)

p.163-167
Just another neuroleptic

Miglustat (Zavesca

p.168-170
In type 1 Gaucher

Ibritumomab (Zevalin

p.171-173
Interesting concept, disappointing in practice

Darbepoetin alfa (New indication/New dosage)

p.174-176
No proven advantage in chemotherapy-induced anaemia

Epoetin and cancer outcome

p.175

Use of epoetin in oncology: many, many uncertainties

p.176

Adverse Effects


Free  Celecoxib still on the market: but for whose benefit ?

p.177-178
Patients are still exposed to the risks of a drug that provides no advantage

Infliximab: lymphomas and severe hepatitis

p.179

Deaths linked to injectable olanzapine

p.179
Olanzapine is not the best sedative in the emergency setting

Telithromycin : another interacting macrolide

p.179
Interaction with oral anticoagulant

Diphosphonates: ocular risks

p.179
Beware inflammatory eye disorders

Heart failure: caution required with angiotensin II receptor antagonist and betabloker combinations

p.183

Reviews


Angiotensin II receptor antagonists and heart failure

p.180-186
Angiotensin-converting enzyme inhibitors (ACE) are still the first-line option

Role of angiotensin II receptor antagonists in heart failure and acute myocardial infarction: Prescrire's proposals

p.185

Insulin in type 2 diabetes

p.187-193
A useful alternative, despite limited assessment based on surrogate endpoints
Insuline can be a helpful alternative in type 2 diabetes

Weight gain with insulin and oral antidiabetics

p.191

Outlook


Free  Drugs: incomplete and inconsistent "official" information

p.194-195
Large discrepancies between information distributed worldwide via summaries of product characteristics (SPCs) and standard information

Free  Management of conflict of interest: the example of the Cochrane Collaboration

p.195-196
Strong rules have been set up to shield as much as possible systematic reviews from conflict of interest

Free  Euthanasia: a "kit" sold in Belgian pharmacies

p.197
Around 20 euthanasias reported monthly since decriminalisation in 2002

Forum


Free  Do some French academic clinicians have interests in common with the pharmaceutical industry?

p.198-199
Evidence abounds

Free  Internet addresses: just how reliable are they?

p.199

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe